Aktienanalyse zu Carlsmed, Inc. (CARL)CARLCarlsmed, Inc.

Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights for each surgeon. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures. It operates in the Healthcare sector.

Carlsmed Inc. is a good buy right now due to its recent revenue growth of 57% year-over-year in Q2 2026, reaching $18.9 million, and a strong gross margin of 76.8%. Despite a current price of $13.41, analysts have set a price target as high as $24, suggesting significant upside potential. The main risk is the widening net loss of $10.5 million in Q2 2026, which indicates ongoing financial challenges.